Replicor Inc.

Viral disease-focused Antios Therapeutics Inc. hopes to move its active site polymerase inhibitor nucleotide (ASPIN) ATI-2173 into a 12-month Phase IIb study later this year, which could provide the

Even without its noteworthy involvement in developing the antiviral Veklury to treat COVID-19 patients and subsequent manufacturing and distribution agreements, Gilead Sciences, Inc. has had a busy

Some sponsors are enjoying an extra serving of regulatory cranberry sauce this week after their development programs received a breakthrough therapy designation (BTD) from the US FDA. Psilocybin BTD R

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer